Food Allergy Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Food allergy is an abnormal immune response to a food protein, causing reproducible adverse reactions on exposure to a specific food that are absent when the food is avoided. IgE-mediated food allergy — the most clinically significant form — produces immediate reactions (within minutes to 2 hours of ingestion) ranging from oral allergy syndrome (localised mouth tingling), urticaria, and angioedema to severe anaphylaxis with cardiovascular compromise. It affects 3-6% of adults and 6-8% of children globally, with the most common triggers being peanut, tree nuts, milk, egg, wheat, soy, fish, and shellfish.

Food allergy management has undergone a fundamental shift over the past decade. The traditional approach — strict lifelong avoidance plus emergency adrenaline auto-injector — remains the cornerstone of safe management, but is now complemented by food oral immunotherapy (OIT): a structured treatment using progressively increasing doses of food protein to induce desensitisation, enabling patients to tolerate amounts of the allergenic food sufficient to protect against accidental exposure. OIT does not train patients to freely eat unlimited amounts of the allergenic food, but substantially reduces the risk of severe anaphylaxis from accidental exposure — a constant life-limiting anxiety for food-allergic individuals and their families.

The LEAP (Learning Early About Peanut Allergy) trial published in NEJM (2015) changed prevention paradigms — demonstrating that early introduction of peanut in high-risk infants (with eczema and/or egg allergy) dramatically reduces peanut allergy development (3.2% vs 17.3% at 60 months). LEAP follow-up studies (LEAP-On) showed protection persisted after peanut was removed from diet. Early weaning guidelines in the UK, US, and Australia now recommend early introduction of common allergens including peanut, egg, and wheat into infant diet rather than avoidance.

For food-allergic families seeking OIT through specialist allergy centres abroad, India and Singapore have developed specialist paediatric allergy OIT programmes at substantially lower cost than Western centres.

Peanut allergy — the most common cause of fatal food anaphylaxis — affects 1-2% of children in Western countries, with prevalence rising. Palforzia (AR101, Aimmune Therapeutics) is an FDA-approved (2020) and EMA-approved (2020) peanut OIT product — standardised peanut flour powder — that achieves desensitisation (tolerating at least 600 mg peanut protein, the equivalent of approximately 2 peanuts) in 67% of treated children aged 4-17, significantly reducing anaphylaxis risk from accidental exposure. Peanut allergy affects 1-2% of Western populations and causes 30-40% of fatal food anaphylaxis cases.

Cow's milk allergy — the most common food allergy in infants (2-3% of infants) — most children naturally acquire tolerance by school age, but approximately 15-20% have persistent milk allergy beyond 5 years. Milk OIT programmes achieve desensitisation to 200 ml milk in 60-75% of participants. Egg allergy similarly shows high rates of natural tolerance acquisition, with 80% tolerating egg by age 16 — baked milk and baked egg challenges (in the form of muffins and waffles) identify children who tolerate extensively heated forms and can begin the baked egg ladder toward raw egg tolerance. Tree nut allergies (cashew, walnut, hazelnut, almond, pistachio, Brazil nut) are increasingly targeted with cross-reactive or nut-specific OIT protocols in research and specialist clinic settings. Wheat allergy and sesame allergy OIT protocols are under active development.

Food OIT candidates are individuals with confirmed IgE-mediated food allergy (positive skin prick test and/or elevated specific IgE, confirmed by positive graded oral food challenge if necessary) who wish to reduce their anaphylaxis risk from accidental exposure. Palforzia peanut OIT is licensed for ages 4-17 with confirmed peanut allergy and a history of at least one reaction requiring treatment. OIT programmes for milk, egg, and tree nuts are offered in specialist allergy centres though without licensed commercial products.

Contraindications to OIT include: active severe eosinophilic oesophagitis (a complication in 1-5% of OIT participants causing severe heartburn and dysphagia); uncontrolled asthma (OIT-related systemic reactions are more severe in asthmatics); severe cardiovascular disease; and inability to comply with the graduated build-up protocol. OIT is not suitable for patients with a history of severe non-IgE-mediated food reactions (FPIES — food protein-induced enterocolitis syndrome — requires different management). Patients and families must understand that OIT is not a cure — daily maintenance doses are required indefinitely to maintain desensitisation, and stopping OIT reverses tolerance. Exercise, illness, and alcohol amplify OIT reaction risk and require dose modification.

Allergen avoidance and emergency preparedness remains the primary management strategy for all food allergy patients: complete avoidance of the allergenic food and all products containing it; careful label reading and understanding of allergen labelling law (the 14 major allergens must be declared on pre-packed food in the EU; the 9 major allergens in the US); education of schools, nurseries, restaurants, and caregivers; and mandatory prescription of adrenaline auto-injector (EpiPen 0.3 mg for adults and children above 25 kg, EpiPen Jr 0.15 mg for children 15-25 kg, or Jext) for any patient with a history of anaphylaxis or a food allergy where anaphylaxis risk is significant.

Oral immunotherapy (OIT) involves three phases: initial dose escalation day (administering increasing doses every 20-30 minutes in clinic to identify the starting daily home dose); build-up phase (weekly or bi-weekly clinic visits increasing the daily home dose over 4-6 months); and maintenance phase (daily fixed maintenance dose continued at home indefinitely). During the build-up phase, doses of approximately 3-6 mg to 300-600 mg of peanut protein are administered under supervision. Sublingual immunotherapy (SLIT) using small subthreshold doses placed under the tongue is under investigation for food allergy as a safer alternative to OIT with lower risk of systemic reactions, though efficacy is somewhat lower than OIT. Epicutaneous immunotherapy (EPIT) — a skin patch delivering food allergen — has completed Phase 3 trials for peanut allergy (Viaskin Peanut, DBV Technologies), awaiting regulatory approval; it offers non-ingestion delivery particularly suited for young children.

Palforzia peanut OIT in the PALISADE Phase 3 trial achieved desensitisation (exit food challenge tolerance of at least 600 mg peanut protein) in 67.2% of participants aged 4-17 versus 4% in placebo — an effect that reduces the risk of anaphylaxis from accidental exposure to low levels of peanut protein from typical cross-contamination. Quality of life studies in food allergy consistently show that successful OIT produces substantial improvement in food allergy-related anxiety and quality-of-life scores for both children and parents — the constant vigilance, social restriction, and anxiety associated with severe food allergy cause significant psychological burden.

Milk OIT achieves complete freedom to consume unlimited milk in 50-60% of participants at the end of the protocol — though regular milk consumption must continue to maintain tolerance. The baked milk ladder (from well-baked muffin to soft baked cheese to unheated milk) achieves full tolerance in 50-80% of milk-allergic children over 12-18 months in a structured programme. Natural acquisition of tolerance is documented in regular follow-up food challenges: approximately 20% of peanut-allergic children acquire natural tolerance by age 18, and 50-60% of milk and egg-allergic children are tolerant by school age — these can be identified by OFC and diet expansion encouraged.

Anaphylaxis during OIT is the most significant risk, occurring during initial dose escalation day procedures in 1-5% of participants. During the home build-up phase, systemic reactions requiring adrenaline auto-injector use occur in 3-10% of patients — this is why patients and families are thoroughly trained in early symptom recognition and adrenaline auto-injector use before beginning OIT, and why all OIT participants must have two adrenaline auto-injectors available at all times.

Eosinophilic oesophagitis (EoE) — a complication characterised by severe oesophageal eosinophilic infiltration causing heartburn, dysphagia, and food impaction — develops in approximately 1-5% of OIT participants, most commonly with milk OIT, and requires OIT discontinuation and proton pump inhibitor treatment. Persistent localised oral symptoms (lip tingling, throat scratching) during home dosing are very common (40-60%) and do not indicate serious reaction — most resolve with pre-medication or dose adjustment. Participants must maintain strict daily dosing compliance — missed doses require dose stepping back to the previous lower dose, as tolerance is lost within days without continued exposure, and attempting the previously reached dose after a gap may cause severe reaction.

OIT requires intensive specialist follow-up during the build-up phase — weekly or bi-weekly clinic visits for dose increase and reaction assessment, with home dosing diary review. Once at maintenance, clinic visits at 3-monthly then 6-monthly intervals monitor compliance, any intercurrent reactions, growth (for children), and quality-of-life outcomes. Specific IgE and SPT monitoring during OIT typically shows an initial rise in specific IgE (a normal immunological response to increasing allergen exposure) followed by gradual decline with sustained desensitisation.

After completing the maintenance phase, the question of whether to attempt food allergy challenge off OIT (to test for sustained unresponsiveness — a more durable state of tolerance persisting after OIT stops) is offered in some research protocols. Sustained unresponsiveness is achieved in 20-30% of peanut OIT completers after a period off OIT — though currently patients are generally advised to continue maintenance dosing indefinitely. All food-allergic patients — whether or not on OIT — should continue to carry two adrenaline auto-injectors, wear medical alert identification, and have an individualised written allergy action plan detailing early and severe reaction recognition and emergency treatment steps.

Palforzia peanut OIT in the United States costs approximately $890 per month ($10,680 per year) for the drug itself, with insurance coverage available from many major insurers but not universal. Additional costs include specialist allergy clinic visits for dose escalation (approximately 6-10 clinic visits during build-up at $200-$500 each) and two adrenaline auto-injectors ($300-$700 annually). Total first-year cost of Palforzia peanut OIT may reach $15,000-$20,000. In the United Kingdom, Palforzia was not NICE-recommended as of 2023 due to cost-effectiveness concerns; NHS food allergy OIT programmes using unbranded peanut flour are offered at some specialist paediatric allergy centres.

Specialist paediatric allergy centres at AIIMS, Apollo Children's Hospital, and Manipal Hospitals in India offer unlicensed OIT programmes for peanut, milk, and egg allergy using custom allergen preparations at $500-$2,000 for the complete programme including all build-up visits, maintenance monitoring, and adrenaline auto-injector training. Singapore General Hospital and KK Women's and Children's Hospital in Singapore offer food OIT at $2,000-$6,000 per programme. Adrenaline auto-injectors (EpiPen equivalent) cost $20-$50 in India versus $300+ in the US without insurance.

Strict allergen avoidance with adrenaline auto-injector remains the safest and most universally applicable alternative to OIT for families who do not wish to pursue desensitisation or for whom OIT is contraindicated. For many families with severe peanut allergy, the anxiety reduction and accidental exposure protection provided by OIT is the primary driver — those with milder allergy or who manage well with avoidance may reasonably choose to continue with avoidance management.

Omalizumab (anti-IgE) as an adjunct to food OIT is being studied in the ARC010 trial — pre-treatment with omalizumab before OIT build-up appears to reduce the frequency and severity of OIT-related systemic reactions, potentially enabling faster build-up and improving safety in high-risk patients. Omalizumab monotherapy (without OIT) has also shown modest protection against accidental peanut and multi-food reactions in a Phase 3 trial (OUtMATCH) — particularly in young children where OIT compliance is challenging. This represents a significant advance for families who cannot undergo OIT, though omalizumab monotherapy does not achieve the degree of desensitisation of OIT. Antihistamines are not an appropriate treatment for food anaphylaxis — adrenaline is the only life-saving treatment and must be given first in anaphylaxis, not antihistamines.